European Journal of Molecular & Clinical Medicine
ISSN 2515-8260 Volume 07, Issue 07, 2020

Acute Myocardial Infarction And Its Associated Therapy

Amandeep Kaur[1]

[1]Department of Medical Laboratory Sciences, Lovely Professional University, Punjab
E-mail: amandeep.24931@lpu.co.in

ABSTRACT:

Acute myocardial infarction (AMI) is one of the common diseases in developing countries.(Sathisha et al., 2011)It is generally known as a heart attack, which occurs when there israpid blockage in flow of blood in one or more of Coronary arteries and decreases the supply of blood to heart muscle, leading to necrosis in which enormous death of cells andpermanent damage occur. If blockage is severe, then heart faces cardiac halt. This is very common because ofblockage occur in coronary artery following splitting of atherosclerotic plaque in which uneven collection of lipids,more commonly cholesterol and fatty acid as well as WBC's specifically macrophagesoccur in walls of artery.AMI is one of an exampleof coronary artery disease, that results into greater than 2.4 million expiries in USA, greater than 4 million expiries in Europe and northern Asia,(Nichols, Townsend, Scarborough, & Rayner, 2014) as well as greater than one third of deaths in advanced countries per year. In this review article, the pathophysiology of acute myocardial infarction along with some uses of drugs is discussed.

Keywords:Acute myocardial infarction, Cardiac arrest, Atherosclerotic plaques

1. INTRODUCTION:

MI is a pathological process established by diminishedsupply of blood to myocardium. In US there are near about 600,000 to 800,000 people suffer attacks from this disease every year.(Balotin, 1959) In current years, higher facilities in analysis and incredibleadvances in treatment have decreased death rate. Large number of deaths happen due to this disease; but those who survive, undergorestrictingproblems. Statistics of mortality and restrictingproblems arereduced by differential analysis of patient whoare suffering from chest pains and additional symptoms distinctive of MI.(Rytter, Troelsen, & Beck-Nielsen, 1985) The analysis of AMI is based upon history, clinical outcomes, and through ECG changes. There are many general symptoms which can be used as adjuncts. The incidence of AMI often requires quick decision. Understanding about order of pathological alterations happen and potential changes in role of myocardium, thought to beessential for quick therapy. Briefly, 11 ischemic changes resultinto necrosis in muscles within first few days after thebeginning of MI. Second and third week of healing leads to fibrosis and growth of collateral circulation(Rytter et al., 1985). Minimum duration of six weeks isessential for most MI to considered as cured. The occurrence of attack depends upon condition ofblood circulation to coronary artery and reliability of myocardium after infarct. Some possible obstacles of cardiovascular can be curedby good approach in therapy. History and symptoms of patient is enough to make diagnosis for those who suffered an attack of myocardial. Changes in ECG can also beappreciated but not very vital. The analysis must be recognized

through evidence of muscle necrosis. Several risk factors which leads to AMI includes smoking, physical activity, alcohol consumption, dyslipidemia, hypertension, Diabeties mellitus, Obesity/BMI, stress gout, age gender, periodontal diseases.(Rathore, Singh, & Mahat, 2018)Cardiovascular disease comprises heart disease which includesMI, angina, stroke, high BP, congestive heart blockage, artery toughening, and other diseases related to circulatory system. CVD is thought to be number one reason for death in America, more than 40% of deaths every year also occur due to this disease. On an average, 1 death because of CVD occurs each 33 seconds in United States. Along with mortality, poorly managed CVD can lead to long-term disability of heart, heart failure, strokes, and end-stage renal disease. CVD is one of the serious issue regarding public health that needs more attention to encourageconsciousness and treatment, to both, health care providers as well as to public.

Epidemiology:

AMI is one of the greatest severe indicator of coronary artery disease(CAD), that leads to nearby 2·4 million expiries in America, greater than 4 million expiries in Europe as well as in northern Asia,(Nichols et al., 2014) also greater than one third expiries in developed nations per year.(Yeh et al., 2010)High use of evidenttreatments and alterations in lifestyle, have encouragedsignificantdecreases in mortality from CAD in currenttimes.(Nichols et al., 2014)However, MI retainsextensivefootmark on health worldwide, disturbing greater than 7 million peopleglobally every year. Compatibly, its financial impact is marvelous; in year 2010, greater than 1.1 million US hospitalizationswas there because of MI.(Heidenreich et al., 2011) Since in the middle of 1990s there was astable drop inquantity of patients having ST-segment elevation myocardial infarction (STEMI), slighterrise in NSTEMI, leads into totaldecline in MI.(Yeh et al., 2010)Currently, NSTEMI contains 60−75% of all MI.(O'Gara et al., 2013; Yeh et al., 2010)Additional per year deaths from STEMI has been dropped fromlast two decades i.e. 5−6% and 7−18%,(O'Gara et al., 2013)anevidence to improvements in pharmacological, reperfusion, and precautionaryapproaches.

CHD mortality dropped in last four decades in USA as life expectation increased the usage of age-related rates to defineCHD mortality complicates fact that drop largely denotes the delay of CHD deathtill adult age. Thus, rate of CHD increase parallel withrise in life expectation.(Walsh, Yalow, & Berson, 1970) As many people live with heart related disease, the load of prevailing disease with various difficulties is rising. Thus, the point of recognizing person with heart disease, assessing prevalence and outcome of disease and in what wayit has evolved over time becomeimportant as multi-layered approaches to minimize the load of disease which includes drug research, clinical experiments and plans have influenced cardiologyexercise for decades and areexpectedto continue to do so in future. Here, MI plays a key part in determining the risk of cardiac disease.(Knudsen, Steenstrup, Byrjalsen, Hildebrandt, & Sørensen, 1989)

Over the past three to four decades the observational features of acute myocardial infarction have significantly improved.Since 1987, the measured rate of hospitalization in the United States for AMI has decreased by 4 to 5 per cent per year.(Schlattner, Tokarska-Schlattner, & Wallimann, 2006)Nonetheless, about 550,000 in first episodes and 200,000 chronic episodes of AMI occur each year.Universally, ischemic heart disease has been the chief contributor to disease burden, as measured on basis of life-years adapted for disability.(Ingwall et al., 1985) Around the same time, the global burden of CD and AMI has moved to low- and middle-income nations, where over 80% cardiovascular disease deaths occur worldwide.(Hawkins & Tan, 1999) The risk factor is directly linked to revenue, with high risk factor load in high income countries and the lowest load in low-income countries, among 156,424 people in 17 countries who were monitored for an average of 4.1 year.While,opposite relationship with income isrenowned for rates with AMI. Mitigation of high risk factor burden in higher-

income nations is due to improved usage of preventive events and procedures for revascularization.(Mozaffarian et al., 2016)

Pathophysiology:

AMI is divided into STEMI and NSTEMI.(O'Gara et al., 2013) Unstable angina also known as acute coronary syndrome, as this is aforthcomingoriginator to MI. Unstable angina have related mechanism for diseases occurrence in NSTEMI, and these are collectively known as non-ST-segment elevation ACS i.e.NSTE-ACS. In many cases, MI is because ofsplitting of atherosclerotic plaque or we can say that sue to erosion ofendothelium of coronary artery which is denoted as type 1.(Libby, 2013; O'Gara et al., 2013) Severe stenosis in which the diameter is ≥70% is essential to remove angina; but, these kind of stenosis have less ability to cause type 1 myocardial infarction as it is consist of dense fibrous caps which are difficult to break, and deposit circulation occurs. While susceptible plaques incline to have 30−50% stenosis, tinny fibrous caps, and comprise high number of lipid-laden macrophagesa kind of inflammatory cells.(Libby, 2013; O'Gara et al., 2013) when plaque get ruptured, it discharges its thrombogenic substances, leads intoactivation of platelet, initiation of cascade for coagulation, formation of thrombus as well asdownstream formation of atherosclerotic remains. This hyper coagulable condition can also cause rupturing of more number vulnerable fibroatheromas, and thus there can be additional lesion.(Libby, 2013) At finalenecrosis of myocyte takes place which can bedetected by rise in cardiac biomarkers in blood at periphery. Many factors causingischemia includes either the vessel is partly or entirely occluded, occlusion period, amount of supply to myocardium layer, existence of collateral, and suitability of reperfusion nextto treatment.Intrial animal it was observed that temperature also shows impacts upon size of infarct, whereas, previously it was observed that hemodynamic situation and myocardiumdemand for oxygen has comparatively less importance for magnitude of infarct.(Murray et al., 2015) The development of infarctoccurs in wave front manner, beginning from sub endocardial layers in centralarea which is at danger and continuingto sub epicardial layer and further to zone border which is at risk with constantperiod of coronary obstruction.(Murray et al., 2012) The advancedprogress of MI with duration of blockage of coronary artery is depend upon species, because of variation in innate collateral flowas well as in innate confrontation to myocardial ischemia. In humans, 30-50% of riskyzone stillremainspractical and so recovered by reperfusion within 4-6 hour from start of signs of angina, as measured from magnetic resonance imaging and analysis of biomarkers.(Yusuf et al., 2014) Even after 12hour of coronary obstruction, feasible myocardium and interventional reperfusion can borderthe mass of infarct.(DeWood et al., 1980)

PPCI was introduced which is an idealmanner of reperfusion in most nations and areaswhereprocess can be performed with speed and high accuracy however, pharma invasive strategy is only practical in many portions of developing world.(Reimer, Lowe, Rasmussen, & Jennings, 1977)While reperfusion is compulsoryto salvage ischemic myocardium from imminent infarction, reperfusion also imposesfurther injury which is irreversible and cause enlarged size of infarct and dysfunction microvascular. Occurrence of deadly reperfusion injury has been long discussed but appreciation of post-conditioning phenomenon, it become unequallyflawless that reperfusion causes irreversible injury and alteration of reperfusion weakensinjury.(Reimer & Jennings, 1979) For better understanding the lack of consistencybetween numerous positive animal study and difficult answer to clinical area, a conversation on pathophysiological thoughtsdescribing myocardial ischemia/reperfusion injury is clinically related.(Mehilli et al., 2009) The infarcted myocardium is describedviamyofibrillar reduction bands, inflamed/or ruptured mitochondria, rupturing of sarcolemma, damage of microvascular, hemorrhage, and infiltrated leukocytes.(Maroko et al.,

1972) These signs imitatenecrosis which typically become more obvious and possiblyenhancedthroughoutreperfusion.(Kennedy et al., 1988; Van de Werf, 2014) Calcium surplusin cells via reverse mode Na^+/Ca^{2+}interchange after excess of sodium viaNa^+/H^+exchanger(Body & Order; Simoons et al., 1985), oscillatory discharge and re uptake of Ca^{2+} insarcoplasmic reticulum which results in uncoordinated and extrememyofibrillar contractions(Hartzler et al., 1983),destruction of cytoskeleton(Keeley, Boura, & Grines, 2003), along withadditionalcreation of reactive oxygen species all together pay to necrotic cell death(Przyklenk, 1997).

Necrosis can bemeasured asfreemanner of cell demise, while extracontrolledtype of cell decease also take place in infracting myocardium, but theinfluence depending upon quantity to infarct size is not clear.(Zhao et al., 2003) Apoptosis cell death which depend upon energy withfragmentation of DNA and lack of inflammatory reactionis introduced extrinsically via sarcolemma receptors and intrinsically withdischarge of cytochrome *C* by injured mitochondria.(Ladilov, Siegmund, & Piper, 1995) Disclosure of mitochondrial permeability transition pore, also important for necrotic as well as apoptotic death of cardio myocyte.(Bernardi, Rasola, Forte, & Lippe, 2015) Autophagy, process of degradation of lysosomal protein,chiefly proteins from mitochondria and functions for reuse of proteins also take place in cardiac death. Necroptosis also started by initiation of specific receptor interacting kinase and nearly shares properties with necrosis and apoptosis.(Singh et al., 2014) The impact of different manners of cell death to infarction or cardioprotection is unclear, part for mitochondria is critical in all;measured modes of cell death might showprecise targets for pharmacological cardio protection.(Oerlemans et al., 2012)The flowin coronary artery with ruptured plaque and overlaid thrombosis is not a single reason of myocardial ischemia but afterwardrepair of coronary flow is alsogoal of ischemia/reperfusion injury.(Oerlemans et al., 2013) Ischemia/reperfusion in coronary flowestablishesdysfunction of microvascular, chiefly by amplified capillary permeability and edema. Coronary micro embolization of atherosclerotic debrisdecreasedvasomotion after endothelial and damage of vascular smooth muscle(Dauber et al., 1990; Garcia-Dorado, Andres-Villarreal, Ruiz-Meana, Inserte, & Barba, 2012) along with discharge of vasoconstriction substances from atherosclerotic lesions(Heusch et al., 2009) like leukocyte, platelet, and erythrocyte accumulation in microcirculation [70] and at last capillary damage and hemorrhage.(Niccoli, Burzotta, Galiuto, & Crea, 2009) Impaired myocardial run of bloodin spite of restoration of epicardial coronary was first to report.(Niccoli, Scalone, Lerman, & Crea, 2016) No reflow observed in 35% patient after STEMI andincidence of analysisbe influenced by different techniques of measurement, ranging 10% by angiography to 60% by MRI.(Hamirani, Wong, Kramer, & Salerno, 2014) The connection between myocardium as well as coronary microvascular ischemia/reperfusion injury is veryuncertain, even though they are linked. Postponed hypothermia after 30 min of reperfusion decreases noreflow. Perhaps, there ismutual pathophysiologic tool likecreation of RO whichtriggers myocardial and coronary microvascular ischaemia/reperfusion damage, howeverbydiverseeffect on both sections.(Hori et al., 1991)

Treatments for acute myocardial infarction:

Numerousagents like antiplatelet are administered to control myocardial infarction.Randomexperiments shown drop in death rate or MI of higher than 50% patents using aspirin related with placebo in patient suffering from ACS.(Cairns et al., 1985; Group, 1990)Strategies recommended quantity of aspirin (162−325 mg) immediately following MI, whileundefined low dosageof aspirin(75−100 mg),preferred as secondary inhibition, because it remain operational as advanced doses for preventing ischemic events but causea lesser amount of bleeding.(Amsterdam et al., 2014; Members et al., 2012; O'Gara et al., 2013)

Clopidogrel is second generation thienopyridine whichpermanentlyantagonizes platelet ADP receptor P2Y-12, and activeinhinderingactivation and accumulation of platelets. The CURE trial arbitrarily assigned 12562 patients with NSTEMI to aspirin only or aspirin and clopidogrel (300 mg loading followed by 75 mg daily),displayed20% drop in danger related to cardiovascular death, non-fatal MI, and stroke with clopidogrel ,at an overhead of amplified major bleeding.(Reed, Rossi, & Cannon, 2017)Cangrelor is intravenous, revocable ADP receptor antagonist, with fast and strong P2Y12 inhibition in 2 min.(Reed et al., 2017)*Glycoprotein IIb/IIIa inhibitors which* includes abciximab, tirofiban, and eptifibatidedeliverstrong inhibition to platelet accumulation, restrictivethrombus spread at expense of amplified risk of bleeding.

2. DISCUSSION:

It is obvious that MI is one of leading cause of morbidity and mortality throughout the world. It is responsible for over 15% of mortality per year, among the huge majority of people suffering from NSTEMI than STEMI. Many risk factors are responsible for onset of AMI. It is associated with accumulation of white blood cells which leads into the formation of atherosclerotic plaques and which further get ruptures to cause heart attack. Many strategies are planned to cure and also to reduce the number of death rates because of heart attacks.

3. REFERENCES:

[1] Amsterdam, E. A., Wenger, N. K., Brindis, R. G., Casey, D. E., Ganiats, T. G., Holmes, D. R., . . . Kontos, M. C. (2014). 2014 AHA/ACC guideline for the management of patients with non–ST-elevation acute coronary syndromes: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *Journal of the American College of Cardiology, 64*(24), 2645-2687.

[2] Balotin, N. M. (1959). Myocardial infarction, its diagnosis and treatment: literature review. *Chest, 36*(1), 86-94.

[3] Bernardi, P., Rasola, A., Forte, M., & Lippe, G. (2015). The mitochondrial permeability transition pore: channel formation by F-ATP synthase, integration in signal transduction, and role in pathophysiology. *Physiological reviews, 95*(4), 1111-1155.

[4] Body, G., & Order, J. SS Iyengar*, Girish S Godbole*** Consultant Cardiologist, Manipal Hospital, Bangalore;** Consultant Cardiologist, Vikram Hospital, Bangalore.

[5] Cairns, J. A., Gent, M., Singer, J., Finnie, K. J., Froggatt, G. M., Holder, D. A., . . . Myers, M. G. (1985). Aspirin, sulfinpyrazone, or both in unstable angina: results of a Canadian multicenter trial. *New England Journal of Medicine, 313*(22), 1369-1375.

[6] Dauber, I. M., VanBenthuysen, K. M., McMurtry, I. F., Wheeler, G. S., Lesnefsky, E. J., Horwitz, L. D., & Weil, J. V. (1990). Functional coronary microvascular injury evident as increased permeability due to brief ischemia and reperfusion. *Circulation Research, 66*(4), 986-998.

[7] DeWood, M. A., Spores, J., Notske, R., Mouser, L. T., Burroughs, R., Golden, M. S., & Lang, H. T. (1980). Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. *New England Journal of Medicine, 303*(16), 897-902.

[8] Garcia-Dorado, D., Andres-Villarreal, M., Ruiz-Meana, M., Inserte, J., & Barba, I. (2012). Myocardial edema: a translational view. *Journal of molecular and cellular cardiology, 52*(5), 931-939.

[9] Group, R. (1990). Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. *The Lancet, 336*(8719), 827-830.

[10] Hamirani, Y. S., Wong, A., Kramer, C. M., & Salerno, M. (2014). Effect of microvascular obstruction and intramyocardial hemorrhage by CMR on LV remodeling and outcomes after myocardial infarction: a systematic review and meta-analysis. *JACC: Cardiovascular Imaging, 7*(9), 940-952.

[11] Hartzler, G. O., Rumerford, B. D., McConahay, D. R., Johnson Jr, W. L., McCallister, B. D., Gura Jr, G. M., . . . Crockett, J. E. (1983). Percutaneous transluminal coronary angioplasty with and without thrombolytic therapy for treatment of acute myocardial infarction. *American heart journal, 106*(5), 965-973.

[12] Hawkins, R., & Tan, H. (1999). Comparison of the diagnostic utility of CK, CK-MB (activity and mass), troponin T and troponin I in patients with suspected acute myocardial infarction. *Singapore medical journal, 40*(11), 680-684.

[13] Heidenreich, P., Trogdon, J., Khavjou, O., Butler, J., Dracup, K., Ezekowitz, M., . . . Khera, A. (2011). American Heart Association Advocacy Coordinating C. *Stroke C, Council on Cardiovascular R, Intervention, Council on Clinical C, Council on E, Prevention, Council on A, Thrombosis, Vascular B, Council on C, Critical C, Perioperative, Resuscitation, Council on Cardiovascular N, Council on the Kidney in Cardiovascular D, Council on Cardiovascular, 5*.

[14] Heusch, G., Kleinbongard, P., Böse, D., Levkau, B., Haude, M., Schulz, R., & Erbel, R. (2009). Coronary microembolization: from bedside to bench and back to bedside. *Circulation, 120*(18), 1822-1836.

[15] Hori, M., Gotoh, K., Kitakaze, M., Iwai, K., Iwakura, K., Sato, H., . . . Kamada, T. (1991). Role of oxygen-derived free radicals in myocardial edema and ischemia in coronary microvascular embolization. *Circulation, 84*(2), 828-840.

[16] Ingwall, J. S., Kramer, M. F., Fifer, M. A., Lorell, B. H., Shemin, R., Grossman, W., & Allen, P. (1985). The creatine kinase system in normal and diseased human myocardium. *New England Journal of Medicine, 313*(17), 1050-1054.

[17] Keeley, E. C., Boura, J. A., & Grines, C. L. (2003). Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. *The Lancet, 361*(9351), 13-20.

[18] Kennedy, J. W., Martin, G. V., Davis, K. B., Maynard, C., Stadius, M., Sheehan, F., & Ritchie, J. (1988). The Western Washington intravenous streptokinase in acute myocardial infarction randomized trial. *Circulation, 77*(2), 345-352.

[19] Knudsen, J., Steenstrup, B., Byrjalsen, I., Hildebrandt, P., & Sørensen, S. (1989). At what level of serum total creatine kinase activity can measurement of serum creatine kinase MB isoenzyme activity be omitted in suspected myocardial infarction? *Scandinavian journal of clinical and laboratory investigation, 49*(7), 661-665.

[20] Ladilov, Y., Siegmund, B., & Piper, H. (1995). Protection of reoxygenated cardiomyocytes against hypercontracture by inhibition of Na+/H+ exchange. *American Journal of Physiology-Heart and Circulatory Physiology, 268*(4), H1531-H1539.

[21] Libby, P. (2013). Mechanisms of acute coronary syndromes and their implications for therapy. *N Engl J Med, 368*, 2004-2013.

[22] Maroko, P., Libby, P., Ginks, W., Bloor, C., Shell, W., Sobel, B., & Ross, J. (1972). Coronary artery reperfusion: I. Early effects on local myocardial function and the extent of myocardial necrosis. *The Journal of clinical investigation, 51*(10), 2710-2716.

[23] Mehilli, J., Kastrati, A., Schulz, S., Früngel, S., Nekolla, S. G., Moshage, W., . . . Dirschinger, J. (2009). CLINICAL PERSPECTIVE. *Circulation, 119*(14), 1933-1940.
[24] Members, A. T. F., Steg, P. G., James, S. K., Atar, D., Badano, L. P., Lundqvist, C. B., . . . Ducrocq, G. (2012). ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC). *European heart journal, 33*(20), 2569-2619.
[25] Mozaffarian, D., Benjamin, E., Go, A., Arnett, D., Blaha, M., Cushman, M., . . . Fullerton, H. (2016). on behalf of the American Heart Association Statistics Committee and Stroke Statistics Subcommittee [published correction appears in Circulation. 2016; 133: e599]. *Heart disease and stroke statistics—2016 update: a report from the American Heart Association. Circulation, 133*, e38-e360.
[26] Murray, C. J., Barber, R. M., Foreman, K. J., Ozgoren, A. A., Abd-Allah, F., Abera, S. F., . . . Abu-Raddad, L. J. (2015). Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990–2013: quantifying the epidemiological transition. *The Lancet, 386*(10009), 2145-2191.
[27] Murray, C. J., Vos, T., Lozano, R., Naghavi, M., Flaxman, A. D., Michaud, C., . . . Abdalla, S. (2012). Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. *The Lancet, 380*(9859), 2197-2223.
[28] Niccoli, G., Burzotta, F., Galiuto, L., & Crea, F. (2009). Myocardial no-reflow in humans. *Journal of the American College of Cardiology, 54*(4), 281-292.
[29] Niccoli, G., Scalone, G., Lerman, A., & Crea, F. (2016). Coronary microvascular obstruction in acute myocardial infarction. *European heart journal, 37*(13), 1024-1033.
[30] Nichols, M., Townsend, N., Scarborough, P., & Rayner, M. (2014). Cardiovascular disease in Europe 2014: epidemiological update. *European heart journal, 35*(42), 2950-2959.
[31] O'Gara, P. T., Kushner, F. G., Ascheim, D. D., Casey, D. E., Chung, M. K., De Lemos, J. A., . . . Franklin, B. A. (2013). 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *Journal of the American College of Cardiology, 61*(4), e78-e140.
[32] Oerlemans, M. I., Koudstaal, S., Chamuleau, S. A., de Kleijn, D. P., Doevendans, P. A., & Sluijter, J. P. (2013). Targeting cell death in the reperfused heart: pharmacological approaches for cardioprotection. *International journal of cardiology, 165*(3), 410-422.
[33] Oerlemans, M. I., Liu, J., Arslan, F., den Ouden, K., van Middelaar, B. J., Doevendans, P. A., & Sluijter, J. P. (2012). Inhibition of RIP1-dependent necrosis prevents adverse cardiac remodeling after myocardial ischemia–reperfusion in vivo. *Basic research in cardiology, 107*(4), 270.
[34] Przyklenk, K. (1997). Lethal Myocardial" Reperfusion Injury": The Opinions of Good Men. *Journal of thrombosis and thrombolysis, 4*(1), 5.
[35] Rathore, V., Singh, N., & Mahat, R. K. (2018). Risk factors for acute myocardial infarction: A review. *EURASIAN JOURNAL OF MEDICAL INVESTIGATION, 2*(1), 1-7.
[36] Reed, G. W., Rossi, J. E., & Cannon, C. P. (2017). Acute myocardial infarction. *The Lancet, 389*(10065), 197-210.

[37] Reimer, K. A., & Jennings, R. B. (1979). The" wavefront phenomenon" of myocardial ischemic cell death. II. Transmural progression of necrosis within the framework of ischemic bed size (myocardium at risk) and collateral flow. *Laboratory investigation; a journal of technical methods and pathology, 40*(6), 633-644.

[38] Reimer, K. A., Lowe, J. E., Rasmussen, M. M., & Jennings, R. B. (1977). The wavefront phenomenon of ischemic cell death. 1. Myocardial infarct size vs duration of coronary occlusion in dogs. *Circulation, 56*(5), 786-794.

[39] Rytter, L., Troelsen, S., & Beck-Nielsen, H. (1985). Prevalence and mortality of acute myocardial infarction in patients with diabetes. *Diabetes care, 8*(3), 230-234.

[40] Sathisha, T., Manjunatha Goud, B., Avinash, S., Jeevan, S., Devi, O. S., & Devaki, R. (2011). Microalbuminuria in Non-diabetic, Non-hypertensive Myocardial Infraction in South Indian Patients with Relation to Lipid Profile anf Cardiac Markers. *Journal of Clinical and Diagnostic Research, 5*(6), 1158-1160.

[41] Schlattner, U., Tokarska-Schlattner, M., & Wallimann, T. (2006). Mitochondrial creatine kinase in human health and disease. *Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease, 1762*(2), 164-180.

[42] Simoons, M., De Zwaan, C., Verheugt, F., Remme, W., Serruys, P., Bär, F., . . . Lubsen, J. (1985). Improved survival after early thrombolysis in acute myocardial infarction: a randomised trial by the Interuniversity Cardiology Institute in The Netherlands. *The Lancet, 326*(8455), 578-581.

[43] Singh, K. K., Yanagawa, B., Quan, A., Wang, R., Garg, A., Khan, R., . . . Teoh, H. (2014). Autophagy gene fingerprint in human ischemia and reperfusion. *The Journal of thoracic and cardiovascular surgery, 147*(3), 1065-1072. e1061.

[44] Van de Werf, F. (2014). The history of coronary reperfusion. *European heart journal, 35*(37), 2510-2515.

[45] Walsh, J. H., Yalow, R., & Berson, S. A. (1970). Detection of Australia antigen and antibody by means of radioimmunoassay techniques. *The Journal of infectious diseases, 121*(5), 550-554.

[46] Yeh, R. W., Sidney, S., Chandra, M., Sorel, M., Selby, J. V., & Go, A. S. (2010). Population trends in the incidence and outcomes of acute myocardial infarction. *New England Journal of Medicine, 362*(23), 2155-2165.

[47] Yusuf, S., Rangarajan, S., Teo, K., Islam, S., Li, W., Liu, L., . . . Liu, T. (2014). Cardiovascular risk and events in 17 low-, middle-, and high-income countries. *New England Journal of Medicine, 371*(9), 818-827.

[48] Zhao, Z.-Q., Corvera, J. S., Halkos, M. E., Kerendi, F., Wang, N.-P., Guyton, R. A., & Vinten-Johansen, J. (2003). Inhibition of myocardial injury by ischemic postconditioning during reperfusion: comparison with ischemic preconditioning. *American Journal of Physiology-Heart and Circulatory Physiology, 285*(2), H579-H588.